MA26221A1 - Nouveaux preconcentres de microemulsion d'analogue de la cyclosporine. - Google Patents

Nouveaux preconcentres de microemulsion d'analogue de la cyclosporine.

Info

Publication number
MA26221A1
MA26221A1 MA27599A MA27599A MA26221A1 MA 26221 A1 MA26221 A1 MA 26221A1 MA 27599 A MA27599 A MA 27599A MA 27599 A MA27599 A MA 27599A MA 26221 A1 MA26221 A1 MA 26221A1
Authority
MA
Morocco
Prior art keywords
preconcenters
novel cyclosporin
cyclosporin analog
microemulsion
analog microemulsion
Prior art date
Application number
MA27599A
Other languages
English (en)
Inventor
Selvaraj Naicker
Randall W Yatscoff
Robert T Foster
Original Assignee
Isotechnika Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isotechnika Inc filed Critical Isotechnika Inc
Publication of MA26221A1 publication Critical patent/MA26221A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
MA27599A 2001-10-19 2004-03-26 Nouveaux preconcentres de microemulsion d'analogue de la cyclosporine. MA26221A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34620101P 2001-10-19 2001-10-19
US37059702P 2002-04-05 2002-04-05

Publications (1)

Publication Number Publication Date
MA26221A1 true MA26221A1 (fr) 2004-07-01

Family

ID=26994747

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27599A MA26221A1 (fr) 2001-10-19 2004-03-26 Nouveaux preconcentres de microemulsion d'analogue de la cyclosporine.

Country Status (28)

Country Link
US (5) US7060672B2 (fr)
EP (2) EP1435910B9 (fr)
JP (3) JP2005506990A (fr)
KR (1) KR100978836B1 (fr)
CN (1) CN1274294C (fr)
AR (1) AR036852A1 (fr)
AT (1) ATE437629T1 (fr)
AU (1) AU2002333098B2 (fr)
BR (1) BR0213661A (fr)
CA (1) CA2461730C (fr)
CO (1) CO5580835A2 (fr)
DE (1) DE60233150D1 (fr)
DK (1) DK1435910T3 (fr)
ES (1) ES2330625T3 (fr)
HR (1) HRP20040354B1 (fr)
IL (3) IL160761A0 (fr)
MA (1) MA26221A1 (fr)
ME (1) MEP89008A (fr)
MX (1) MXPA04003623A (fr)
MY (1) MY145753A (fr)
NO (1) NO20042028L (fr)
NZ (1) NZ531946A (fr)
PL (1) PL206018B1 (fr)
PT (1) PT1435910E (fr)
RU (1) RU2317067C2 (fr)
TN (1) TNSN04070A1 (fr)
WO (1) WO2003032949A1 (fr)
ZA (1) ZA200402268B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1435910B9 (fr) * 2001-10-19 2010-02-03 Isotechnika Inc. Nouveaux preconcentres en microemulsion d'analogues de cyclosporine
CA2518265A1 (fr) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Nouvelles cyclosporines
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
US7378391B2 (en) * 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
WO2006041631A2 (fr) 2004-10-06 2006-04-20 Amr Technology, Inc. Alcynes de cyclosporine, et leur utilite comme agents pharmaceutiques
EP1996067B1 (fr) * 2005-05-19 2013-04-10 The Board Of Governors For Higher Education Surveillance de la cyclosporine dans la salive
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
US20070264349A1 (en) * 2006-03-07 2007-11-15 Novavax, Inc. Nano-structured compositions and methods of making and using the same
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
US7696166B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
JP2010508357A (ja) * 2006-10-31 2010-03-18 ワイス エルエルシー ホスホリパーゼ酵素阻害剤の処方
CL2007003143A1 (es) * 2006-10-31 2008-01-25 Wyeth Corp Composicion farmaceutica que comprende un compuesto derivado de indol y un sistema portador que comprende 10-50% de un primer solubilizante, 5-50% de un segundo solubilizante, 10-30% de un primer diluyente y 1-15% de un segundo diluyente; proceso de prepracion; y forma de dosificacion.
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
BRPI0909185A2 (pt) 2008-03-20 2015-08-25 Virun Inc Derivado de vitamina e e seus usos
MX2010010050A (es) 2008-03-20 2011-03-15 Virun Inc Star Emulsiones que incluyen un derivado de polietilen glicol de tocoferol.
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
EP2440185B1 (fr) * 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Systemes d'administration de medicament topique pour une utilisation ophtalmique
EP2509583B1 (fr) 2009-12-10 2019-05-15 Merck Patent GmbH COMPOSITION PHARMACEUTIQUE COMPRENANT DES OLIGOPEPTIDES, préférablement de Cilengitide
EP2563164B1 (fr) * 2010-03-23 2016-06-29 Virun, Inc. Nanoemulsions comprenant des ester d'acide gras de sucrose
IT1404931B1 (it) * 2010-06-11 2013-12-09 Medivis S R L Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
WO2011162802A1 (fr) 2010-06-21 2011-12-29 Virun, Inc. Compositions contenant des composés non polaires
US20110319467A1 (en) * 2010-06-23 2011-12-29 Bhiku Patel Absorption Enhancement of Statins and Omega Fatty Acids
JP5840682B2 (ja) * 2010-06-25 2016-01-06 フイルメニツヒ ソシエテ アノニムＦｉｒｍｅｎｉｃｈ Ｓａ 成分送達系
US20120095098A1 (en) * 2010-10-18 2012-04-19 Bhiku Patel Bioavailability Enhancement Delivery System
US9044394B2 (en) * 2010-10-18 2015-06-02 PruGen IP Holdings, Inc. Bioavailability enhancement delivery composition
AU2011342284C1 (en) 2010-12-15 2017-07-13 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
US8609684B2 (en) * 2011-12-12 2013-12-17 PruGen IP Holdings, Inc. Solubilization and bioavailability of acetaminophen
WO2013090461A1 (fr) * 2011-12-12 2013-06-20 PruGen IP Holdings, Inc. Composition de libération de statines améliorant la biodisponibilité
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
GB201222455D0 (en) * 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
MX2017015936A (es) * 2014-06-18 2018-04-18 Chugai Pharmaceutical Co Ltd Nueva composicion farmaceutica que comprende agentes tensioactivos no ionicos.
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
DK3373976T3 (da) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd Topiske formuleringer og anvendelser deraf
NZ785158A (en) 2016-02-29 2025-03-28 Sun Pharmaceutical Ind Ltd Topical cyclosporine-containing formulations and uses thereof
EP3548896B1 (fr) 2016-12-01 2021-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation de la concentration de igg contre uchl1 pour diagnostiquer le syndrome néphrotique idiopathique sensible aux stéroïdes
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US10286036B2 (en) 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
WO2019077123A1 (fr) 2017-10-20 2019-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et kits pour identifier si un sujet est atteint ou risque d'être atteint d'une myopathie auto-immune
AU2019386859A1 (en) * 2018-11-26 2021-05-27 Hepion Pharmaceuticals, Inc. Pharmaceutical formulations of cyclosporine analogs
WO2020115262A1 (fr) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation de cd26 et cd39 en tant que nouveaux marqueurs phénotypiques pour évaluer la maturation de lymphocytes t ffoxp3+ et leurs utilisations à des fins de diagnostic
CN113508129B (zh) 2019-01-15 2025-02-18 法国国家健康和医学研究院 突变的白介素-34(il-34)多肽及其在治疗中的用途
EP3981432B1 (fr) 2019-03-27 2024-07-31 Tokyo Medical University Agent thérapeutique pour le syndrome de wolfram
WO2021224890A1 (fr) 2020-05-07 2021-11-11 Aurinia Pharmaceuticals Inc. Méthodes de traitement ou de prévention d'infection par coronavirus
KR102449537B1 (ko) * 2022-01-27 2022-10-05 주식회사 나노메디팜 근적외선을 이용하여 진단 생검 또는 종양 제거 수술 중에 종양 식별과 절제면 구분을 위한 종양 표적 진단 조영제
WO2024153636A1 (fr) 2023-01-17 2024-07-25 Institut National de la Santé et de la Recherche Médicale Vasorine en tant que biomarqueur et biocible en néphrologie
EP4751102A1 (fr) 2023-07-24 2026-06-03 Institut National de la Santé et de la Recherche Médicale Procédés pour déterminer si un sujet souffrant de néphrite lupique (ln) est sensible à une thérapie par induction
WO2025045894A1 (fr) 2023-08-28 2025-03-06 Institut National de la Santé et de la Recherche Médicale Méthodes et trousses de diagnostic de cause du syndrome néphrotique et d'orientation de la thérapie

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH614931A5 (fr) * 1975-11-04 1979-12-28 Sandoz Ag
DE2819094A1 (de) * 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
CH641356A5 (en) 1979-02-27 1984-02-29 Sandoz Ag Pharmaceutical compositions containing cyclosporin
DE3260468D1 (en) * 1981-01-09 1984-09-06 Sandoz Ag Novel cyclosporins
CH667274A5 (de) * 1984-03-23 1988-09-30 Sandoz Ag Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
GB8903804D0 (en) 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
EP0194972B1 (fr) 1985-03-11 1992-07-29 Sandoz Ag Cyclosporines
US4764503A (en) * 1986-11-19 1988-08-16 Sandoz Ltd. Novel cyclosporins
HU205861B (en) * 1986-12-19 1992-07-28 Sandoz Ag Process for producing hydrosole of pharmaceutically effective material
JP2577049B2 (ja) * 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
ATE95193T1 (de) 1987-06-17 1993-10-15 Sandoz Ag Cyclosporine und deren benutzung als arzneimittel.
ATE110784T1 (de) * 1987-06-19 1994-09-15 Sandoz Ag Zyklische peptolide.
DE3830494B4 (de) 1987-09-15 2006-05-18 Novartis Ag Wasserlösliche Monoester als Solubilisatoren für pharmakologische Wirkstoffe und pharmazeutische Hilfsstoffe
ES2033086T3 (es) * 1988-01-29 1993-03-01 Sankyo Company Limited Un procedimiento para la preparacion de una composicion farmaceutica.
HU201567B (en) * 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
US5350741A (en) * 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
JP2792862B2 (ja) 1988-07-30 1998-09-03 寛治 高田 経口腸溶製剤
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
GB8823621D0 (en) 1988-10-07 1988-11-16 Madhok R Compositions containing cyclosporins
DE3843241A1 (de) 1988-12-22 1990-06-28 Skrezek Christian Nephroprotektive infusionsloesung
BE1003009A5 (fr) 1989-02-09 1991-10-22 Sandoz Sa Nouvelles compositions pharmaceutiques a base de cyclosporines.
US5540931A (en) 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5284826A (en) * 1989-07-24 1994-02-08 Sandoz Ltd. 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5681964A (en) * 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
FI111730B (fi) * 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
GB9105705D0 (en) * 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
WO1992018104A1 (fr) 1991-04-19 1992-10-29 Vestar, Inc. Formulation et procedes pharmaceutiques
US5620971A (en) * 1991-05-09 1997-04-15 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US6262022B1 (en) * 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
US5248499A (en) * 1991-10-07 1993-09-28 Genentech, Inc. Control of microbial infections in transplant patients
GB9203886D0 (en) 1992-02-24 1992-04-08 Sandoz Ltd Improvements in or relating to organic compounds
GB9208712D0 (en) * 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
US5759566A (en) * 1992-07-28 1998-06-02 Poli Industria Chimica Spa Microemulsion pharmaceutical compositions for the delivery of pharmaceutically active agents
US5654000A (en) * 1992-07-28 1997-08-05 Poli Industria Chimica S.P.A. Pharmaceutical compositions for transmucosal delivery of peptides
CZ278863B6 (en) 1992-09-07 1994-07-13 Galena Medicinal preparations with n-methylated cyclic undecapeptides
DK0589843T3 (da) 1992-09-25 2002-04-02 Novartis Ag Cyclosporinholdige farmaceutiske præparater
EP0666752A4 (fr) 1992-10-16 1996-09-11 Smithkline Beecham Corp Microemulsions therapeutiques.
WO1994008603A1 (fr) 1992-10-16 1994-04-28 Smithkline Beecham Corporation Compositions
AU5539294A (en) 1992-12-24 1994-07-19 Hemagen/Pfc Fluorocarbon emulsions
US6113921A (en) * 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
NZ247516A (en) * 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
CN1077800C (zh) 1993-07-01 2002-01-16 韩美药品工业株式会社 环孢菌素软胶囊组合物
US5639474A (en) * 1993-07-01 1997-06-17 Hanmi Pharm. Ind., Ltd. Cyclosporin soft capsule composition
DK1033128T4 (da) * 1993-09-28 2012-03-19 Scherer Gmbh R P Blød gelatinekapselfremstilling
US5840707A (en) 1993-10-04 1998-11-24 Albany Medical College Stabilizing and delivery means of biological molecules
US6022852A (en) * 1993-10-22 2000-02-08 Hexal Ag Pharmaceutical composition containing cyclosporin A
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
WO1995022343A1 (fr) 1994-02-17 1995-08-24 Shiseido Company, Ltd. Composition d'emulsion a base de cyclosporine
DE69535127T2 (de) * 1994-03-18 2007-02-15 Supernus Pharmaceuticals, Inc. Emulgierte arzneistoffabgabesysteme
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
FI100692B (fi) * 1994-05-24 1998-02-13 Leiras Oy Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä
WO1995032726A1 (fr) * 1994-06-01 1995-12-07 Yuhan Corporation Composition a base de cyclosporine et son procede de preparation
CH686865A5 (de) * 1994-06-15 1996-07-31 Gergely Gerhard Pharmazeutische Zubereitung mit einem hydrophoben Wirkstoff und einem Brausesystem, sowie Verfahren zur Herstellung der Zubereitung.
EP0697214A1 (fr) 1994-07-19 1996-02-21 Vestar, Inc. Formulations pharmaceutiques avec de la cyclosporine liposomale
WO1996003113A1 (fr) 1994-07-22 1996-02-08 G.D. Searle & Co. Systeme d'apport de medicaments auto-emulsifiant
US5635159A (en) * 1994-08-26 1997-06-03 Abbott Laboratories Aerosol drug formulations containing polyglycolyzed glycerides
MY129435A (en) 1994-10-26 2007-04-30 Novartis Ag Pharmaceutical microemulsion preconcentrates
US5603951A (en) * 1994-11-09 1997-02-18 Hanmi Pharm. Ind. Co., Ltd. Cyclosporin-containing soft capsule compositions
HU215966B (hu) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
KR100239799B1 (ko) 1995-01-21 2000-02-01 손경식 경구투여용 사이클로스포린 에이 고체미셀분산체, 이의 제조 방법 및 고형제제
GB9512100D0 (en) * 1995-06-14 1995-08-09 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
IE75744B1 (en) * 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
JPH11504028A (ja) * 1995-04-24 1999-04-06 イースム リサーチ ディベロップメント カンパニー オブ ザ ヒーブル ユニバーシティ オブ エルサレム 油／水エマルジョンを作り出す自己乳化性配合物
EP0825849A1 (fr) 1995-05-19 1998-03-04 Abbott Laboratories Formulations auto-emulsifiantes de medicaments lipophiles
US5635161A (en) 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
US5693336A (en) * 1995-06-07 1997-12-02 Nexstar Pharmaceuticals, Inc. Blood stable liposomal cyclosporin formulations
US5656287A (en) * 1995-06-07 1997-08-12 Nexstar Pharmaceuticals, Inc. Liposomal cyclosporin formulations as agents for immunosuppression and multiple drug resistant indications
DE19521974A1 (de) 1995-06-16 1996-12-19 Hexal Pharmaforschung Gmbh Pharmazeutische Zubereitung mit Cyclosporin A
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
DE789561T1 (de) 1995-08-25 1999-06-10 Sangstat Medical Corp., Menlo Park, Calif. Orale cyclosporinformulierungen
EP0760237A1 (fr) * 1995-08-30 1997-03-05 Cipla Limited Microémulsions huile-dans-l'eau
NZ280689A (en) * 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
CZ288631B6 (cs) * 1996-01-18 2001-08-15 Galena, A. S. Léčivé přípravky s obsahem cyklosporinu
KR970064620A (ko) 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
CA2248192A1 (fr) 1996-03-12 1997-09-18 Picower Institute For Medical Research Traitement de l'infection a vih par action sur le recepteur de la cyclophiline de cellules hotes
US5660858A (en) * 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
US5958876A (en) * 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
DK0869810T3 (da) 1996-06-19 2005-02-07 Novartis Ag Cyclosporinholdige blöde kapselpræparater
KR980008239A (ko) * 1996-07-26 1998-04-30 김충환 사이클로스포린-함유 약학적 조성물
DE69736750T2 (de) * 1996-07-30 2007-08-16 Novartis Ag Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
CZ288739B6 (cs) * 1996-08-01 2001-08-15 Galena, A. S. Cyklosporin obsahující léčivé přípravky
CZ267796A3 (cs) * 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
CA2185600A1 (fr) 1996-09-16 1998-03-17 Bernard Charles Sherman Concentres hydrosolubles renfermant des cyclosporines
US5798333A (en) * 1996-09-17 1998-08-25 Sherman; Bernard C. Water-soluble concentrates containing cyclosporins
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
NZ314060A (en) 1997-01-13 1997-08-22 Bernard Charles Sherman Pharmaceutical microemulsion preconcentrate comprising cyclosporin dissolved in a solvent system comprising hydrophobic solvent(s) and surfactant(s)
PT988046E (pt) 1997-01-30 2004-12-31 Novartis Ag Composicoes farmaceuticas sem oleo contendo ciclosporina a
US6306434B1 (en) * 1997-02-12 2001-10-23 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
EP0979647A4 (fr) 1997-02-27 2006-07-19 Nippon Shinyaku Co Ltd Emulsion grasse s'administrant par voie orale
HU228855B1 (en) * 1997-03-12 2013-06-28 Abbott Lab Hydrophilic binary systems for the administration of cyclosporine
US6258783B1 (en) * 1997-04-29 2001-07-10 Bernard Charles Sherman Emulsion preconcentrate comprising a cyclosporin and acetylated monoglyceride
NZ314702A (en) * 1997-04-29 1998-07-28 Bernard Charles Sherman Pharmaceutical composition comprising a cyclosporin in a solvent system of acetylated monoglycerides and a surfactant and optionally a hydrophilic solvent
FR2762843B1 (fr) * 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
IN188719B (fr) * 1997-09-08 2002-11-02 Panacea Biotec Ltd
US6187747B1 (en) * 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
US6346511B1 (en) * 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
TR199901008T1 (xx) * 1997-09-09 2000-02-21 Select Release, L.C. Kaplanm�� partik�ller, yap�m� ve kullan�m y�ntemleri.
NZ328751A (en) * 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
DE69832984T2 (de) * 1997-10-08 2006-09-21 Isotechnika, Inc., Edmonton DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN
UA65587C2 (en) * 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
US6028067A (en) * 1997-12-05 2000-02-22 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
US6063762A (en) * 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
US6284268B1 (en) * 1997-12-10 2001-09-04 Cyclosporine Therapeutics Limited Pharmaceutical compositions containing an omega-3 fatty acid oil
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
DE19810655A1 (de) 1998-03-12 1999-09-16 Univ Eberhard Karls Arzneimittel mit einem Gehalt an Ciclosporin
ES2215277T3 (es) 1998-08-18 2004-10-01 Panacea Biotec Limited Composicion de ciclosporina que comprende un vehiculo hidrofilo.
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2001021154A2 (fr) * 1999-09-21 2001-03-29 Rtp Pharma Inc. Compositions particulaires, a surface modifiee, de substances biologiquement actives
WO2001028519A1 (fr) * 1999-10-20 2001-04-26 Vesifact Ag Microemulsions preconcentrees et microemulsions correspondantes
JP2001122779A (ja) 1999-10-26 2001-05-08 Toyo Capsule Kk 経口投与用シクロスポリン含有ミクロエマルジョン濃縮液
JP2001240558A (ja) 2000-02-29 2001-09-04 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。
DE10015463B4 (de) 2000-03-29 2008-01-10 Heide, Peter Edgar, Dr. Creme in Form einer überwässerten Wasser-in-Öl-Emulsion
DK1151755T3 (da) 2000-05-04 2005-06-27 Panacea Biotec Ltd Farmaceutisk præparat indeholdende cyclosporin som aktiv bestanddel
WO2001087324A1 (fr) 2000-05-17 2001-11-22 Viron Therapeutics, Inc. Compositions et des procédés favorisant l'immunosuppression
DE10029404B4 (de) 2000-06-15 2009-10-29 Jagotec Ag Arzneiformulierung enthaltend Ciclosporin und deren Verwendung
US6740636B2 (en) 2000-07-31 2004-05-25 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection
EP1435910B9 (fr) * 2001-10-19 2010-02-03 Isotechnika Inc. Nouveaux preconcentres en microemulsion d'analogues de cyclosporine

Also Published As

Publication number Publication date
NZ531946A (en) 2005-09-30
US20030171264A1 (en) 2003-09-11
JP2005506990A (ja) 2005-03-10
DE60233150D1 (de) 2009-09-10
CN1274294C (zh) 2006-09-13
EP1435910A1 (fr) 2004-07-14
CA2461730A1 (fr) 2003-04-24
TNSN04070A1 (en) 2006-06-01
US20140249092A1 (en) 2014-09-04
NO20042028L (no) 2004-05-14
PL206018B1 (pl) 2010-06-30
US7429562B2 (en) 2008-09-30
EP2116228A1 (fr) 2009-11-11
US20090054311A1 (en) 2009-02-26
US7829533B2 (en) 2010-11-09
US7060672B2 (en) 2006-06-13
ZA200402268B (en) 2005-05-25
IL160761A (en) 2010-11-30
WO2003032949A1 (fr) 2003-04-24
IL160761A0 (en) 2004-08-31
EP1435910B9 (fr) 2010-02-03
RU2317067C2 (ru) 2008-02-20
CA2461730C (fr) 2012-05-15
JP2009073850A (ja) 2009-04-09
IL195892A (en) 2013-09-30
US20060217309A1 (en) 2006-09-28
BR0213661A (pt) 2004-10-26
RU2004110936A (ru) 2005-05-27
MEP89008A (en) 2011-12-20
US20110136744A1 (en) 2011-06-09
PT1435910E (pt) 2009-09-07
MY145753A (en) 2012-03-30
DK1435910T3 (da) 2009-11-09
ATE437629T1 (de) 2009-08-15
HK1062525A1 (en) 2004-11-12
HRP20040354A2 (en) 2005-02-28
AR036852A1 (es) 2004-10-06
AU2002333098B2 (en) 2006-03-16
CO5580835A2 (es) 2005-11-30
JP2012158609A (ja) 2012-08-23
MXPA04003623A (es) 2004-12-02
PL370560A1 (en) 2005-05-30
CN1571657A (zh) 2005-01-26
EP1435910B1 (fr) 2009-07-29
KR100978836B1 (ko) 2010-08-30
HRP20040354B1 (en) 2012-10-31
KR20050037418A (ko) 2005-04-21
ES2330625T3 (es) 2009-12-14

Similar Documents

Publication Publication Date Title
ATE437629T1 (de) Neue cyclosporin-analoge mikroemulsionsvorkonzentrate
DZ2196A1 (fr) Compositions nanoparticulaires de cyclosporine a.
EP1453557A4 (fr) Enrobage d'endoprothese ameliore
MA26337A1 (fr) Melanges d'analogues de la cyclosporine et leur usage comme immunomodulateurs.
DK1091975T3 (da) Ny cyclosporin med forbedret aktivitetsprofil
NO20002800D0 (no) Cyklosporinholdig mikroemulsjon, forkonsentratsammensetning
BR0216099B1 (pt) "conjunto de desgaste".
FR2802799B1 (fr) Ensemble de prothese d'epaule
WO2003011115A3 (fr) Agents de contraste multimères ciblés à base de peptides
PT1164847E (pt) Heptapeptidos analogos de oxitocina
EP0789561A4 (fr) Compositions orales de cyclosporine
FR2805456B1 (fr) Prothese totale de genou, du type dit "postero-stabilisee"
DE60124915D1 (de) Synthetische peptide gegen neurologische krankheiten
ITTO20011193A0 (it) Struttura di depuratore d'aria per veicolo.
WO2002000686A3 (fr) Nanodispositifs et biocapteurs bioelastomeres
ATE293126T1 (de) Cyclische hexapeptidderivate
EP1317560A4 (fr) Vecteurs d'adn pouvant s'auto-reorganiser
NO20032963L (no) Peptidforbindelser
BR8103051Y1 (pt) bicicleta infantil.
EP1314428A4 (fr) Preparations d'oct
AR024483A1 (es) Proteinas insecticidas y nematocidas
ITCO20000026A1 (it) A2 s.p.r. scuotitore prenditore raccoglitore per l'olive
DK1181035T3 (da) Praktisk taget oliefri cyclosporinpræparater
Baker Spanning the centuries
IT1307785B1 (it) Impianto e kit per la fabbricazione di accoppiati tessili.